

Bianca Weinstock-Guttman

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/828888/bianca-weinstock-guttman-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

472
papers

21,661
citations

74
h-index

129
g-index

485
ext. papers

24,648
ext. citations

5.1
avg, IF

6.52
L-index

#	Paper	IF	Citations
472	Gene-environment interactions increase the risk of pediatric-onset multiple sclerosis associated with ozone pollution.. <i>Multiple Sclerosis Journal</i> , 2022 , 13524585211069926	5	0
471	Patient-Reported Outcome Severity and Emotional Salience Network Disruption in Multiple Sclerosis.. <i>Brain Imaging and Behavior</i> , 2022 , 1	4.1	0
470	Worsening physical functioning in patients with neuroinflammatory disease during the COVID-19 pandemic.. <i>Multiple Sclerosis and Related Disorders</i> , 2022 , 58, 103482	4	0
469	Preliminary Support of a Behavioral Intervention for Trait Conscientiousness in Multiple Sclerosis.. <i>International Journal of MS Care</i> , 2022 , 24, 45-53	2.3	
468	Cerebral blood flow dependency on systemic arterial circulation in progressive multiple sclerosis.. <i>European Radiology</i> , 2022 , 1	8	
467	COVID-19 Vaccination in Multiple Sclerosis and Inflammatory Diseases: Effects from Disease-Modifying Therapy, Long-Term Seroprevalence and Breakthrough Infections. <i>Vaccines</i> , 2022 , 10, 695	5.3	1
466	A prospective study to validate the expanded timed get-up-and-go in a population with multiple sclerosis.. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2022 , 8, 20552173221099186	2.6	
465	Plasma 24-hydroxycholesterol is associated with narrower common carotid artery and greater flow velocities in relapsing multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2022 , 103906	4	
464	Impact of Cognitive Impairment and Dysarthria on Spoken Language in Multiple Sclerosis. <i>Journal of the International Neuropsychological Society</i> , 2021 , 27, 450-460	3.1	0
463	Discontinuation of disease modifying therapies is associated with disability progression regardless of prior stable disease and age.. <i>Multiple Sclerosis and Related Disorders</i> , 2021 , 57, 103406	4	2
462	Vaccination Against SARS-CoV-2 in Neuroinflammatory Disease: Early Safety/Tolerability Data.. <i>Multiple Sclerosis and Related Disorders</i> , 2021 , 57, 103433	4	7
461	Interpreting change on the Symbol Digit Modalities Test in people with relapsing multiple sclerosis using the reliable change methodology. <i>Multiple Sclerosis Journal</i> , 2021 , 13524585211049397	5	1
460	Functional network dynamics and decreased conscientiousness in multiple sclerosis. <i>Journal of Neurology</i> , 2021 , 1	5.5	1
459	Three-Day Dietary Manipulation in Multiple Sclerosis: Exercise and Fatigue Outcomes. <i>International Journal of MS Care</i> , 2021 , 23, 199-205	2.3	0
458	Nucleus basalis of Meynert damage and cognition in patients with multiple sclerosis. <i>Journal of Neurology</i> , 2021 , 268, 4796-4808	5.5	1
457	The cholesterol autoxidation products, 7-ketocholesterol and 7βhydroxycholesterol are associated with serum neurofilaments in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2021 , 50, 102864	4	1
456	Staging and stratifying cognitive dysfunction in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021 , 1352458521101139	5	

455	Diffusion tensor imaging reveals greater microstructure damage in lesional tissue that shrinks into cerebrospinal fluid in multiple sclerosis. <i>Journal of Neuroimaging</i> , 2021 , 31, 995-1002	2.8	1
454	Late-onset cutaneous reaction to BNT162b2 mRNA COVID-19 vaccine in an immunocompromised patient. <i>Multiple Sclerosis Journal</i> , 2021 , 27, 2291-2292	5	5
453	Interferons and Multiple Sclerosis: Lessons from 25 Years of Clinical and Real-World Experience with Intramuscular Interferon Beta-1a (Avonex). <i>CNS Drugs</i> , 2021 , 35, 743-767	6.7	10
452	Recovery of cognitive function after relapse in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021 , 27, 71-78	5	19
451	Diagnosis of depression in multiple sclerosis is predicted by frontal-parietal white matter tract disruption. <i>Journal of Neurology</i> , 2021 , 268, 169-177	5.5	4
450	Conscientiousness and deterioration in employment status in multiple sclerosis over 3 years. <i>Multiple Sclerosis Journal</i> , 2021 , 27, 1125-1135	5	4
449	Thalamic Nuclei Volumes and Their Relationships to Neuroperformance in Multiple Sclerosis: A Cross-Sectional Structural MRI Study. <i>Journal of Magnetic Resonance Imaging</i> , 2021 , 53, 731-739	5.6	3
448	Leptomeningeal, dura mater and meningeal vessel wall enhancements in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2021 , 47, 102653	4	4
447	Quantifying cognition and fatigue to enhance the sensitivity of the EDSS during relapses. <i>Multiple Sclerosis Journal</i> , 2021 , 27, 1077-1087	5	3
446	Brain atrophy and lesion burden are associated with disability progression in a multiple sclerosis real-world dataset using only T2-FLAIR: The NeuroSTREAM MSBase study. <i>NeuroImage: Clinical</i> , 2021 , 32, 102802	5.3	0
445	Clinical feasibility of longitudinal lateral ventricular volume measurements on T2-FLAIR across MRI scanner changes. <i>NeuroImage: Clinical</i> , 2021 , 29, 102554	5.3	1
444	Quantifying disease pathology and predicting disease progression in multiple sclerosis with only clinical routine T2-FLAIR MRI. <i>NeuroImage: Clinical</i> , 2021 , 31, 102705	5.3	2
443	Visual deficits and cognitive assessment of multiple sclerosis: confounder, correlate, or both?. <i>Journal of Neurology</i> , 2021 , 268, 2578-2588	5.5	3
442	Considering patient age when treating multiple sclerosis across the adult lifespan. <i>Expert Review of Neurotherapeutics</i> , 2021 , 21, 353-364	4.3	0
441	Ocrelizumab treatment for relapsing-remitting multiple sclerosis after a suboptimal response to previous disease-modifying therapy: A nonrandomized controlled trial. <i>Multiple Sclerosis Journal</i> , 2021 , 13524585211035740	5	2
440	Familial History of Autoimmune Disorders Among Patients With Pediatric Multiple Sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021 , 8,	9.1	2
439	Gut microbiome is associated with multiple sclerosis activity in children. <i>Annals of Clinical and Translational Neurology</i> , 2021 , 8, 1867-1883	5.3	6
438	Clinical effects associated with five-year retinal nerve fiber layer thinning in multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2021 , 427, 117552	3.2	2

437	Disease biomarkers in multiple sclerosis: current serum neurofilament light chain perspectives. <i>Neurodegenerative Disease Management</i> , 2021 , 11, 329-340	2.8	1
436	Asymptomatic infection after BNT162b2 mRNA COVID-19 vaccination in multiple sclerosis patient. <i>Acta Neurologica Belgica</i> , 2021 , 1	1.5	1
435	Benchmarks of meaningful improvement on neurocognitive tests in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021 , 13524585211044672	5	0
434	Peripheral nervous system electrodiagnostic abnormalities in predominantly Hispanic Multiple Sclerosis patients. <i>Multiple Sclerosis and Related Disorders</i> , 2021 , 56, 103254	4	0
433	Manifestations and impact of the COVID-19 pandemic in neuroinflammatory diseases. <i>Annals of Clinical and Translational Neurology</i> , 2021 , 8, 918-928	5.3	7
432	Decreasing brain iron in multiple sclerosis: The difference between concentration and content in iron MRI. <i>Human Brain Mapping</i> , 2021 , 42, 1463-1474	5.9	9
431	Multiple Sclerosis in Children: Differential Diagnosis, Prognosis, and Disease-Modifying Treatment.. <i>CNS Drugs</i> , 2021 , 36, 45	6.7	2
430	Association Between Time Spent Outdoors and Risk of Multiple Sclerosis. <i>Neurology</i> , 2021 ,	6.5	1
429	Sex-Specific Differences in Life Span Brain Volumes in Multiple Sclerosis. <i>Journal of Neuroimaging</i> , 2020 , 30, 342-350	2.8	7
428	Functional Connectivity and Structural Disruption in the Default-Mode Network Predicts Cognitive Rehabilitation Outcomes in Multiple Sclerosis. <i>Journal of Neuroimaging</i> , 2020 , 30, 523-530	2.8	8
427	Tonsillectomy in multiple sclerosis patients: Retrospective, case-controlled, exploratory study. <i>Multiple Sclerosis and Related Disorders</i> , 2020 , 42, 102131	4	2
426	Dietary inflammatory index and risk of multiple sclerosis: Findings from a large population-based incident case-control study. <i>Clinical Nutrition</i> , 2020 , 39, 3402-3407	5.9	17
425	Long-standing multiple sclerosis neurodegeneration: volumetric magnetic resonance imaging comparison to Parkinson's disease, mild cognitive impairment, Alzheimer's disease, and elderly healthy controls. <i>Neurobiology of Aging</i> , 2020 , 90, 84-92	5.6	9
424	Infections, Vaccines and Autoimmunity: A Multiple Sclerosis Perspective. <i>Vaccines</i> , 2020 , 8,	5.3	18
423	The role of dietary antioxidant index and index of nutritional quality in MS onset: finding from an Iranian population-based incident case-control study. <i>Nutritional Neuroscience</i> , 2020 , 1-8	3.6	7
422	Real-World Effectiveness of Initial Disease-Modifying Therapies in Pediatric Multiple Sclerosis. <i>Annals of Neurology</i> , 2020 , 88, 42-55	9.4	26
421	Longitudinal analysis of cerebral aqueduct flow measures: multiple sclerosis flow changes driven by brain atrophy. <i>Fluids and Barriers of the CNS</i> , 2020 , 17, 9	7	1
420	Serum neurofilament light chain and optical coherence tomography measures in MS: A longitudinal study. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020 , 7,	9.1	12

419	Differential Diagnosis of Cognitive Decline in Elderly Individuals With Multiple Sclerosis. <i>Cognitive and Behavioral Neurology</i> , 2020 , 33, 294-300	1.6	1
418	Lipoprotein(a) Levels Are Associated with the Size of Extracranial Arteries in Multiple Sclerosis. <i>Journal of Vascular Research</i> , 2020 , 57, 16-23	1.9	5
417	Multiple sclerosis in 2019: predicting progression. <i>Lancet Neurology, The</i> , 2020 , 19, 12-14	24.1	1
416	Cognitive processing speed in pediatric-onset multiple sclerosis: Baseline characteristics of impairment and prediction of decline. <i>Multiple Sclerosis Journal</i> , 2020 , 26, 1938-1947	5	8
415	A multimodal approach to assess the validity of atrophied T2-lesion volume as an MRI marker of disease progression in multiple sclerosis. <i>Journal of Neurology</i> , 2020 , 267, 802-811	5.5	6
414	Late onset multiple sclerosis is associated with more severe ventricle expansion. <i>Multiple Sclerosis and Related Disorders</i> , 2020 , 46, 102588	4	5
413	Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Neurology, The</i> , 2020 , 19, 988-997	24.1	28
412	Neuroprotective associations of apolipoproteins A-I and A-II with neurofilament levels in early multiple sclerosis. <i>Journal of Clinical Lipidology</i> , 2020 , 14, 675-684.e2	4.9	4
411	Relationships Among Circulating Levels of Hemostasis Inhibitors, Chemokines, Adhesion Molecules, and MRI Characteristics in Multiple Sclerosis. <i>Frontiers in Neurology</i> , 2020 , 11, 553616	4.1	1
410	Long-term drug treatment in multiple sclerosis: safety success and concerns. <i>Expert Opinion on Drug Safety</i> , 2020 , 19, 1121-1142	4.1	5
409	Pediatric Multiple Sclerosis Severity Score in a large US cohort. <i>Neurology</i> , 2020 , 95, e1844-e1853	6.5	3
408	Cortical and Deep Gray Matter Perfusion Associations With Physical and Cognitive Performance in Multiple Sclerosis Patients. <i>Frontiers in Neurology</i> , 2020 , 11, 700	4.1	3
407	Apolipoproteins AI and E are associated with neuroaxonal injury to gray matter in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2020 , 45, 102389	4	8
406	Disability Improvement Is Associated with Less Brain Atrophy Development in Multiple Sclerosis. <i>American Journal of Neuroradiology</i> , 2020 , 41, 1577-1583	4.4	2
405	Serum Neurofilament Light Chain Levels are Associated with Lower Thalamic Perfusion in Multiple Sclerosis. <i>Diagnostics</i> , 2020 , 10,	3.8	1
404	High density lipoprotein cholesterol and apolipoprotein A-I are associated with greater cerebral perfusion in multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2020 , 418, 117120	3.2	3
403	Improved relapse recovery in paediatric compared to adult multiple sclerosis. <i>Brain</i> , 2020 , 143, 2733-2741	11.2	20
402	Necessity of technicians for computerized neuropsychological assessment devices in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2020 , 26, 109-113	5	8

401	Dalfampridine benefits ambulation but not cognition in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2020 , 26, 91-98	5	12
400	Fatigue at enrollment predicts EDSS worsening in the New York State Multiple Sclerosis Consortium. <i>Multiple Sclerosis Journal</i> , 2020 , 26, 99-108	5	17
399	Trait Conscientiousness predicts rate of longitudinal SDMT decline in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2020 , 26, 245-252	5	9
398	Lower total cerebral arterial flow contributes to cognitive performance in multiple sclerosis patients. <i>Multiple Sclerosis Journal</i> , 2020 , 26, 201-209	5	18
397	Higher EBV response is associated with more severe gray matter and lesion pathology in relapsing multiple sclerosis patients: A case-controlled magnetization transfer ratio study. <i>Multiple Sclerosis Journal</i> , 2020 , 26, 322-332	5	14
396	Vitamin D genes influence MS relapses in children. <i>Multiple Sclerosis Journal</i> , 2020 , 26, 894-901	5	12
395	Trait Conscientiousness predicts rate of brain atrophy in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2020 , 26, 1433-1436	5	5
394	Serum neurofilament light chain level associations with clinical and cognitive performance in multiple sclerosis: A longitudinal retrospective 5-year study. <i>Multiple Sclerosis Journal</i> , 2020 , 26, 1670-1681	5	33
393	Cholesterol and neurodegeneration: longitudinal changes in serum cholesterol biomarkers are associated with new lesions and gray matter atrophy in multiple sclerosis over 5 years of follow-up. <i>European Journal of Neurology</i> , 2020 , 27, 188-e4	6	12
392	Plasma levels of protein C pathway proteins and brain magnetic resonance imaging volumes in multiple sclerosis. <i>European Journal of Neurology</i> , 2020 , 27, 235-243	6	6
391	MRI biomarkers of disease progression and conversion to secondary-progressive multiple sclerosis. <i>Expert Review of Neurotherapeutics</i> , 2020 , 20, 821-834	4.3	6
390	Efficacy and Safety of 2 Fingolimod Doses vs Glatiramer Acetate for the Treatment of Patients With Relapsing-Remitting Multiple Sclerosis: A Randomized Clinical Trial. <i>JAMA Neurology</i> , 2020 ,	17.2	7
389	Preserved network functional connectivity underlies cognitive reserve in multiple sclerosis. <i>Human Brain Mapping</i> , 2019 , 40, 5231-5241	5.9	20
388	Atrophied Brain T2 Lesion Volume at MRI Is Associated with Disability Progression and Conversion to Secondary Progressive Multiple Sclerosis. <i>Radiology</i> , 2019 , 293, 424-433	20.5	18
387	Teriflunomide effect on humoral response to Epstein-Barr virus and development of cortical gray matter pathology in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2019 , 36, 101388	4	12
386	Admixture mapping reveals evidence of differential multiple sclerosis risk by genetic ancestry. <i>PLoS Genetics</i> , 2019 , 15, e1007808	6	20
385	Lipid profile is associated with decreased fatigue in individuals with progressive multiple sclerosis following a diet-based intervention: Results from a pilot study. <i>PLoS ONE</i> , 2019 , 14, e0218075	3.7	12
384	Response heterogeneity to home-based restorative cognitive rehabilitation in multiple sclerosis: An exploratory study. <i>Multiple Sclerosis and Related Disorders</i> , 2019 , 34, 103-111	4	12

383	miRNA contributions to pediatric-onset multiple sclerosis inferred from GWAS. <i>Annals of Clinical and Translational Neurology</i> , 2019 , 6, 1053-1061	5.3	4
382	Oxysterols and apolipoproteins in multiple sclerosis: a 5 year follow-up study. <i>Journal of Lipid Research</i> , 2019 , 60, 1190-1198	6.3	19
381	No association between variations in extracranial venous anatomy and clinical outcomes in multiple sclerosis patients over 5 years. <i>BMC Neurology</i> , 2019 , 19, 121	3.1	1
380	Aging and Brain Atrophy in Multiple Sclerosis. <i>Journal of Neuroimaging</i> , 2019 , 29, 527-535	2.8	16
379	Epidemiology and treatment of multiple sclerosis in elderly populations. <i>Nature Reviews Neurology</i> , 2019 , 15, 329-342	15	99
378	Vascular aspects of multiple sclerosis: emphasis on perfusion and cardiovascular comorbidities. <i>Expert Review of Neurotherapeutics</i> , 2019 , 19, 445-458	4.3	17
377	Cognitive Profiles of Aging in Multiple Sclerosis. <i>Frontiers in Aging Neuroscience</i> , 2019 , 11, 105	5.3	24
376	Leptomeningeal Contrast Enhancement Is Related to Focal Cortical Thinning in Relapsing-Remitting Multiple Sclerosis: A Cross-Sectional MRI Study. <i>American Journal of Neuroradiology</i> , 2019 , 40, 620-625	4.4	13
375	Effect of Teriflunomide and Dimethyl Fumarate on Cortical Atrophy and Leptomeningeal Inflammation in Multiple Sclerosis: A Retrospective, Observational, Case-Control Pilot Study. <i>Journal of Clinical Medicine</i> , 2019 , 8,	5.1	6
374	Comparative effectiveness of teriflunomide and dimethyl fumarate in patients with relapsing forms of MS in the retrospective real-world Teri-RADAR study. <i>Journal of Comparative Effectiveness Research</i> , 2019 , 8, 305-316	2.1	10
373	Hypertension and heart disease are associated with development of brain atrophy in multiple sclerosis: a 5-year longitudinal study. <i>European Journal of Neurology</i> , 2019 , 26, 87-e8	6	48
372	Abnormal venous postural control: multiple sclerosis-specific change related to gray matter pathology or age-related neurodegenerative phenomena?. <i>Clinical Autonomic Research</i> , 2019 , 29, 329-338 ³	4.3	3
371	Altered nuclei-specific thalamic functional connectivity patterns in multiple sclerosis and their associations with fatigue and cognition. <i>Multiple Sclerosis Journal</i> , 2019 , 25, 1243-1254	5	21
370	Cumulative gadodiamide administration leads to brain gadolinium deposition in early MS. <i>Neurology</i> , 2019 , 93, e611-e623	6.5	19
369	Lifestyle-based modifiable risk factors in multiple sclerosis: review of experimental and clinical findings. <i>Neurodegenerative Disease Management</i> , 2019 , 9, 149-172	2.8	30
368	Serum neurofilament light chain levels associations with gray matter pathology: a 5-year longitudinal study. <i>Annals of Clinical and Translational Neurology</i> , 2019 , 6, 1757-1770	5.3	39
367	High-density lipoprotein cholesterol is associated with multiple sclerosis fatigue: A fatigue-metabolism nexus?. <i>Journal of Clinical Lipidology</i> , 2019 , 13, 654-663.e1	4.9	9
366	Salient Central Lesion Volume: A Standardized Novel Fully Automated Proxy for Brain FLAIR Lesion Volume in Multiple Sclerosis. <i>Journal of Neuroimaging</i> , 2019 , 29, 615-623	2.8	3

365	Decrease in Secondary Neck Vessels in Multiple Sclerosis: A 5-year Longitudinal Magnetic Resonance Angiography Study. <i>Current Neurovascular Research</i> , 2019 , 16, 215-223	1.8	4
364	The role of Epstein-Barr virus in multiple sclerosis: from molecular pathophysiology to imaging. <i>Neural Regeneration Research</i> , 2019 , 14, 373-386	4.5	74
363	Impact of Nutritional Intake on Function in People with Mild-to-Moderate Multiple Sclerosis. <i>International Journal of MS Care</i> , 2019 , 21, 1-9	2.3	14
362	Marijuana Use by Patients with Multiple Sclerosis. <i>International Journal of MS Care</i> , 2019 , 21, 57-62	2.3	8
361	Dietary and lifestyle factors in multiple sclerosis progression: results from a 5-year longitudinal MRI study. <i>Journal of Neurology</i> , 2019 , 266, 866-875	5.5	20
360	Dimethyl Fumarate in the Treatment of Relapsing-Remitting Multiple Sclerosis: Patient Reported Outcomes and Perspectives. <i>Patient Related Outcome Measures</i> , 2019 , 10, 373-384	2.9	3
359	Acquisition of Early Developmental Milestones and Need for Special Education Services in Pediatric Multiple Sclerosis. <i>Journal of Child Neurology</i> , 2019 , 34, 148-152	2.5	2
358	Are Plasma Levels of Vascular Adhesion Protein-1 Associated Both with Cerebral Microbleeds in Multiple Sclerosis and Intracerebral Haemorrhages in Stroke?. <i>Thrombosis and Haemostasis</i> , 2019 , 119, 175-178	7	5
357	Medical History and Multiple Sclerosis: A Population-Based Incident Case-Control Study. <i>Neuroepidemiology</i> , 2019 , 52, 55-62	5.4	2
356	Lower self-report fatigue in multiple sclerosis is associated with localized white matter tract disruption between amygdala, temporal pole, insula, and other connected structures. <i>Multiple Sclerosis and Related Disorders</i> , 2019 , 27, 298-304	4	10
355	Assessment of mesoscopic properties of deep gray matter iron through a model-based simultaneous analysis of magnetic susceptibility and R* - A pilot study in patients with multiple sclerosis and normal controls. <i>NeuroImage</i> , 2019 , 186, 308-320	7.9	11
354	Plasma levels of soluble NCAM in multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2019 , 396, 36-43	3.2	10
353	Impact of fingolimod on clinical and magnetic resonance imaging outcomes in routine clinical practice: A retrospective analysis of the multiple sclerosis, clinical and MRI outcomes in the USA (MS-MRIUS) study. <i>Multiple Sclerosis and Related Disorders</i> , 2019 , 27, 65-73	4	5
352	An Update on the Use of Disease-Modifying Therapy in Pregnant Patients with Multiple Sclerosis. <i>CNS Drugs</i> , 2018 , 32, 161-178	6.7	18
351	Complementary and Alternative Medicine Usage by Multiple Sclerosis Patients: Results from a Prospective Clinical Study. <i>Journal of Alternative and Complementary Medicine</i> , 2018 , 24, 596-602	2.4	14
350	Early infectious exposures are not associated with increased risk of pediatric-onset multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2018 , 22, 103-107	4	
349	No evidence of disease activity in patients receiving fingolimod at private or academic centers in clinical practice: a retrospective analysis of the multiple sclerosis, clinical, and magnetic resonance imaging outcomes in the USA (MS-MRIUS) study. <i>Current Medical Research and Opinion</i> , 2018 , 34, 1431-1440	2.5	4
348	Effect of switching from glatiramer acetate 20 mg/daily to glatiramer acetate 40 mg three times a week on gray and white matter pathology in subjects with relapsing multiple sclerosis: A longitudinal DTI study. <i>Journal of the Neurological Sciences</i> , 2018 , 387, 152-156	3.2	5

347	Longitudinal personality change associated with cognitive decline in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2018 , 1352458517753720	5	16
346	Improved cognitive performance and event-related potential changes following working memory training in patients with multiple sclerosis. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2018 , 4, 2055217317747626	2	15
345	Evaluation of Leptomeningeal Contrast Enhancement Using Pre-and Postcontrast Subtraction 3D-FLAIR Imaging in Multiple Sclerosis. <i>American Journal of Neuroradiology</i> , 2018 , 39, 642-647	4.4	26
344	Assessing No Evidence of Disease Activity Status in Patients with Relapsing-Remitting Multiple Sclerosis Receiving Fingolimod in Routine Clinical Practice: A Retrospective Analysis of the Multiple Sclerosis Clinical and Magnetic Resonance Imaging Outcomes in the USA (MS-MRIUS) Study. <i>CNS</i>	6.7	23
343	Feasibility of Brain Atrophy Measurement in Clinical Routine without Prior Standardization of the MRI Protocol: Results from MS-MRIUS, a Longitudinal Observational, Multicenter Real-World Outcome Study in Patients with Relapsing-Remitting MS. <i>American Journal of Neuroradiology</i> , 2018 , 39, 289-295	4.4	19
342	Interferon For Multiple Sclerosis. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2018 , 8,	5.4	57
341	Effect of dimethyl fumarate on gray and white matter pathology in subjects with relapsing multiple sclerosis: a longitudinal study. <i>European Journal of Neurology</i> , 2018 , 25, 584-e36	6	7
340	Effect of teriflunomide on gray and white matter brain pathology in multiple sclerosis using volumetric and diffusion-tensor imaging MRI measures. <i>Journal of the Neurological Sciences</i> , 2018 , 388, 175-181	3.2	10
339	Preliminary investigation of cognitive function in aged multiple sclerosis patients: Challenges in detecting comorbid Alzheimer disease. <i>Multiple Sclerosis and Related Disorders</i> , 2018 , 22, 52-56	4	12
338	Changes of deep gray matter magnetic susceptibility over 2 years in multiple sclerosis and healthy control brain. <i>NeuroImage: Clinical</i> , 2018 , 18, 1007-1016	5.3	20
337	Trait neuroticism, extraversion, and conscientiousness in multiple sclerosis: Link to cognitive impairment?. <i>Multiple Sclerosis Journal</i> , 2018 , 24, 205-213	5	10
336	Dietary factors and pediatric multiple sclerosis: A case-control study. <i>Multiple Sclerosis Journal</i> , 2018 , 24, 1067-1076	5	17
335	Mapping of thalamic magnetic susceptibility in multiple sclerosis indicates decreasing iron with disease duration: A proposed mechanistic relationship between inflammation and oligodendrocyte vitality. <i>NeuroImage</i> , 2018 , 167, 438-452	7.9	43
334	Genetic risk factors for pediatric-onset multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2018 , 24, 1825-1834	5	25
333	Separate and Combined Influence of Cognitive Impairment and Dysarthria on Functional Communication in Multiple Sclerosis. <i>American Journal of Speech-Language Pathology</i> , 2018 , 27, 1051-1065	3.1	22
332	Brain Iron at Quantitative MRI Is Associated with Disability in Multiple Sclerosis. <i>Radiology</i> , 2018 , 289, 487-496	20.5	48
331	A decline in cognitive function should lead to a change in disease-modifying therapy - Yes. <i>Multiple Sclerosis Journal</i> , 2018 , 24, 1681-1682	5	5
330	Increased CCL18 plasma levels are associated with neurodegenerative MRI outcomes in multiple sclerosis patients. <i>Multiple Sclerosis and Related Disorders</i> , 2018 , 25, 37-42	4	8

329	White matter tract network disruption explains reduced conscientiousness in multiple sclerosis. <i>Human Brain Mapping</i> , 2018 , 39, 3682-3690	5.9	16
328	Infectious exposure, antibiotic use, and multiple sclerosis: A population-based incident case-control study. <i>Acta Neurologica Scandinavica</i> , 2018 , 138, 308-314	3.8	8
327	Fingolimod® Impact on MRI Brain Volume Measures in Multiple Sclerosis: Results from MS-MRIUS. <i>Journal of Neuroimaging</i> , 2018 , 28, 399-405	2.8	8
326	Five-Year Longitudinal Study of Neck Vessel Cross-Sectional Area in Multiple Sclerosis. <i>American Journal of Neuroradiology</i> , 2018 , 39, 1703-1709	4.4	12
325	Walking disability measures in multiple sclerosis patients: Correlations with MRI-derived global and microstructural damage. <i>Journal of the Neurological Sciences</i> , 2018 , 393, 128-134	3.2	20
324	Thalamic white matter in multiple sclerosis: A combined diffusion-tensor imaging and quantitative susceptibility mapping study. <i>Human Brain Mapping</i> , 2018 , 39, 4007-4017	5.9	12
323	Pregnancy Outcomes from the Branded Glatiramer Acetate Pregnancy Database. <i>International Journal of MS Care</i> , 2018 , 20, 9-14	2.3	49
322	Lower Arterial Cross-Sectional Area of Carotid and Vertebral Arteries and Higher Frequency of Secondary Neck Vessels Are Associated with Multiple Sclerosis. <i>American Journal of Neuroradiology</i> , 2018 , 39, 123-130	4.4	21
321	Iron-related gene variants and brain iron in multiple sclerosis and healthy individuals. <i>NeuroImage: Clinical</i> , 2018 , 17, 530-540	5.3	18
320	Brain Atrophy Is Associated with Disability Progression in Patients with MS followed in a Clinical Routine. <i>American Journal of Neuroradiology</i> , 2018 , 39, 2237-2242	4.4	18
319	Heterogeneity in association of remote herpesvirus infections and pediatric MS. <i>Annals of Clinical and Translational Neurology</i> , 2018 , 5, 1222-1228	5.3	17
318	Stress-full life events and multiple sclerosis: A population-based incident case-control study. <i>Multiple Sclerosis and Related Disorders</i> , 2018 , 26, 168-172	4	11
317	Urban air quality and associations with pediatric multiple sclerosis. <i>Annals of Clinical and Translational Neurology</i> , 2018 , 5, 1146-1153	5.3	21
316	Several household chemical exposures are associated with pediatric-onset multiple sclerosis. <i>Annals of Clinical and Translational Neurology</i> , 2018 , 5, 1513-1521	5.3	3
315	Use of newer disease-modifying therapies in pediatric multiple sclerosis in the US. <i>Neurology</i> , 2018 , 91, e1778-e1787	6.5	29
314	Phase 2 Trial of Ibudilast in Progressive Multiple Sclerosis. <i>New England Journal of Medicine</i> , 2018 , 379, 846-855	59.2	131
313	The Effect of Glatiramer Acetate on Retinal Nerve Fiber Layer Thickness in Patients with Relapsing-Remitting Multiple Sclerosis: A Longitudinal Optical Coherence Tomography Study. <i>CNS Drugs</i> , 2018 , 32, 763-770	6.7	6
312	Atrophied Brain Lesion Volume: A New Imaging Biomarker in Multiple Sclerosis. <i>Journal of Neuroimaging</i> , 2018 , 28, 490-495	2.8	35

311	Hemostasis biomarkers in multiple sclerosis. <i>European Journal of Neurology</i> , 2018 , 25, 1169-1176	6	19
310	Impact of Focal White Matter Damage on Localized Subcortical Gray Matter Atrophy in Multiple Sclerosis: A 5-Year Study. <i>American Journal of Neuroradiology</i> , 2018 , 39, 1480-1486	4.4	11
309	Evaluating the association of allergies with multiple sclerosis susceptibility risk and disease activity in a pediatric population. <i>Journal of the Neurological Sciences</i> , 2017 , 375, 371-375	3.2	3
308	Two decades of glatiramer acetate: From initial discovery to the current development of generics. <i>Journal of the Neurological Sciences</i> , 2017 , 376, 255-259	3.2	24
307	Evidence for a causal relationship between low vitamin D, high BMI, and pediatric-onset MS. <i>Neurology</i> , 2017 , 88, 1623-1629	6.5	97
306	Maternal and Perinatal Exposures Are Associated With Risk for Pediatric-Onset Multiple Sclerosis. <i>Pediatrics</i> , 2017 , 139,	7.4	22
305	An Observational Study to Assess Brain MRI Change and Disease Progression in Multiple Sclerosis Clinical Practice-The MS-MRIUS Study. <i>Journal of Neuroimaging</i> , 2017 , 27, 339-347	2.8	13
304	Serum lipid profile changes predict neurodegeneration in interferon- β -treated multiple sclerosis patients. <i>Journal of Lipid Research</i> , 2017 , 58, 403-411	6.3	23
303	Centralized and Local Color Doppler Ultrasound Reading Agreement for Diagnosis of the Chronic Cerebrospinal Venous Insufficiency in Patients with Multiple Sclerosis. <i>Current Neurovascular Research</i> , 2017 , 14, 266-273	1.8	4
302	Global and regional brain atrophy is associated with low or retrograde facial vein flow in multiple sclerosis. <i>Veins and Lymphatics</i> , 2017 , 6,	1.3	2
301	Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patients. <i>Neurology</i> , 2017 , 89, 1584-1593	6.5	42
300	Examining the contributions of environmental quality to pediatric multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2017 , 18, 164-169	4	17
299	Is Multiple Sclerosis Associated With a Lower Intraocular Pressure?. <i>Journal of Neuro-Ophthalmology</i> , 2017 , 37, 265-267	2.6	3
298	Ocrelizumab: a B-cell depleting therapy for multiple sclerosis. <i>Expert Opinion on Biological Therapy</i> , 2017 , 17, 1163-1172	5.4	20
297	Leptomeningeal contrast enhancement is associated with progression of cortical atrophy in MS: A retrospective, pilot, observational longitudinal study. <i>Multiple Sclerosis Journal</i> , 2017 , 23, 1336-1345	5	68
296	Differential effects of aging on motor and cognitive functioning in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2017 , 23, 1385-1393	5	32
295	Interdependence of oxysterols with cholesterol profiles in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2017 , 23, 792-801	5	30
294	Fatigue and Mood States in Nursing Home and Nonambulatory Home-Based Patients with Multiple Sclerosis. <i>International Journal of MS Care</i> , 2017 , 19, 297-302	2.3	2

293 Treatment Considerations in Female MS Patients of Reproductive Age **2017**, 35-48

292 Stable neuropsychiatric status in multiple sclerosis: a 3-year study. *Multiple Sclerosis Journal*, **2016**, 22, 569-74 5 10

291 MRI in the evaluation of pediatric multiple sclerosis. *Neurology*, **2016**, 87, S88-96 6.5 33

290 Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis. *The Cochrane Library*, **2016**, 11, CD009333 5.2 25

289 Synergistic Effects of Reserve and Adaptive Personality in Multiple Sclerosis. *Journal of the International Neuropsychological Society*, **2016**, 22, 920-927 3.1 17

288 Decreased risk of cancer in multiple sclerosis patients and analysis of the effect of disease modifying therapies on cancer risk. *Journal of the Neurological Sciences*, **2016**, 370, 13-17 3.2 15

287 Use of natalizumab in multiple sclerosis: current perspectives. *Expert Opinion on Biological Therapy*, **2016**, 16, 1151-62 5.4 11

286 Factors associated with benign multiple sclerosis in the New York State MS Consortium (NYSMSC). *BMC Neurology*, **2016**, 16, 102 3.1 6

285 Cerebral Microbleeds in Multiple Sclerosis Evaluated on Susceptibility-weighted Images and Quantitative Susceptibility Maps: A Case-Control Study. *Radiology*, **2016**, 281, 884-895 20.5 54

284 Influenza vaccination increases anti-JC virus antibody levels during treatment with Natalizumab: Case report. *Multiple Sclerosis and Related Disorders*, **2016**, 9, 54-5 4 5

283 Humoral response to EBV is associated with cortical atrophy and lesion burden in patients with MS. *Neurology: Neuroimmunology and NeuroInflammation*, **2016**, 3, e190 9.1 24

282 Dicer and microRNA expression in multiple sclerosis and response to interferon therapy. *Journal of Neuroimmunology*, **2016**, 292, 68-78 3.5 24

281 Long-Term Neurocognitive, Psychosocial, and Magnetic Resonance Imaging Outcomes in Pediatric-Onset Acute Disseminated Encephalomyelitis. *Pediatric Neurology*, **2016**, 57, 64-73 2.9 17

280 Randomised natalizumab discontinuation study: taper protocol may prevent disease reactivation. *Journal of Neurology, Neurosurgery and Psychiatry*, **2016**, 87, 937-43 5.5 13

279 Autoimmune Comorbidities Are Associated with Brain Injury in Multiple Sclerosis. *American Journal of Neuroradiology*, **2016**, 37, 1010-6 4.4 16

278 Gut microbiota composition and relapse risk in pediatric MS: A pilot study. *Journal of the Neurological Sciences*, **2016**, 363, 153-7 3.2 110

277 Impact of Pharmacotherapy on Cognitive Dysfunction in Patients with Multiple Sclerosis. *CNS Drugs*, **2016**, 30, 209-25 6.7 20

276 Extended interval dosing of natalizumab in multiple sclerosis. *Journal of Neurology, Neurosurgery and Psychiatry*, **2016**, 87, 885-9 5.5 90

275	Clinical features of neuromyelitis optica in children: US Network of Pediatric MS Centers report. <i>Neurology</i> , 2016 , 86, 245-52	6.5	75
274	Localized atrophy of the thalamus and slowed cognitive processing speed in MS patients. <i>Multiple Sclerosis Journal</i> , 2016 , 22, 1327-36	5	68
273	Increased albumin quotient (QA1b) in patients after first clinical event suggestive of multiple sclerosis is associated with development of brain atrophy and greater disability 48 months later. <i>Multiple Sclerosis Journal</i> , 2016 , 22, 770-81	5	26
272	Cardiovascular risk factors are associated with increased lesion burden and brain atrophy in multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016 , 87, 181-7	5.5	77
271	Multiple Sclerosis Subtypes 2016 , 55-65		
270	Effect of natalizumab on brain atrophy and disability progression in multiple sclerosis patients over 5 years. <i>European Journal of Neurology</i> , 2016 , 23, 1101-9	6	14
269	Characteristics of Children and Adolescents With Multiple Sclerosis. <i>Pediatrics</i> , 2016 , 138,	7.4	52
268	Reserve-related activities and MRI metrics in multiple sclerosis patients and healthy controls: an observational study. <i>BMC Neurology</i> , 2016 , 16, 108	3.1	4
267	Dietary salt intake and time to relapse in paediatric multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016 , 87, 1350-1353	5.5	43
266	Distinct effects of obesity and puberty on risk and age at onset of pediatric MS. <i>Annals of Clinical and Translational Neurology</i> , 2016 , 3, 897-907	5.3	47
265	A case-control study of dietary salt intake in pediatric-onset multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2016 , 6, 87-92	4	43
264	Benchmarks of meaningful impairment on the MSFC and BICAMS. <i>Multiple Sclerosis Journal</i> , 2016 , 22, 1874-1882	5	32
263	Clinical relevance of brain atrophy assessment in multiple sclerosis. Implications for its use in a clinical routine. <i>Expert Review of Neurotherapeutics</i> , 2016 , 16, 777-93	4.3	94
262	Optical coherence tomography and neurodegeneration: are eyes the windows to the brain?. <i>Expert Review of Neurotherapeutics</i> , 2016 , 16, 765-75	4.3	23
261	Aging and multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2016 , 22, 717-25	5	86
260	The US Network of Pediatric Multiple Sclerosis Centers: Development, Progress, and Next Steps. <i>Journal of Child Neurology</i> , 2015 , 30, 1381-7	2.5	16
259	Identifying employed multiple sclerosis patients at-risk for job loss: When do negative work events pose a threat?. <i>Multiple Sclerosis and Related Disorders</i> , 2015 , 4, 409-413	4	22
258	A new perspective on proxy report: Investigating implicit processes of understanding through patient-proxy congruence. <i>Quality of Life Research</i> , 2015 , 24, 2637-49	3.7	8

257	Blood circulating microparticle species in relapsing-remitting and secondary progressive multiple sclerosis. A case-control, cross sectional study with conventional MRI and advanced iron content imaging outcomes. <i>Journal of the Neurological Sciences</i> , 2015 , 355, 84-9	3.2	16
256	A pilot, longitudinal, 24-week study to evaluate the effect of interferon beta-1a subcutaneous on changes in susceptibility-weighted imaging-filtered phase assessment of lesions and subcortical deep-gray matter in relapsing-remitting multiple sclerosis. <i>Therapeutic Advances in Neurological Sciences</i> , 2015 , 8, 10-18	6.6	4
255	Associations between changes in ferritin levels and susceptibility-weighted imaging filtered phase in patients with relapsing-remitting multiple sclerosis over 24 weeks of therapy with subcutaneous interferon beta-1a three times weekly. <i>Journal of Neuroimmunology</i> , 2015 , 281, 44-50	3.5	1
254	Disclosure of disease status among employed multiple sclerosis patients: association with negative work events and accommodations. <i>Multiple Sclerosis Journal</i> , 2015 , 21, 225-34	5	22
253	Cognitive and White Matter Tract Differences in MS and Diffuse Neuropsychiatric Systemic Lupus Erythematosus. <i>American Journal of Neuroradiology</i> , 2015 , 36, 1874-83	4.4	21
252	Protective associations of HDL with blood-brain barrier injury in multiple sclerosis patients. <i>Journal of Lipid Research</i> , 2015 , 56, 2010-8	6.3	33
251	Increased contrast enhancing lesion activity in relapsing-remitting multiple sclerosis migraine patients. <i>NeuroImage: Clinical</i> , 2015 , 9, 110-6	5.3	11
250	Higher weight in adolescence and young adulthood is associated with an earlier age at multiple sclerosis onset. <i>Multiple Sclerosis Journal</i> , 2015 , 21, 858-65	5	39
249	Radiologic MS disease activity during natalizumab treatment interruption: findings from RESTORE. <i>Journal of Neurology</i> , 2015 , 262, 326-36	5.5	16
248	Immunological and short-term brain volume changes in relapsing forms of multiple sclerosis treated with interferon beta-1a subcutaneously three times weekly: an open-label two-arm trial. <i>BMC Neurology</i> , 2015 , 15, 232	3.1	9
247	Simultaneous determination of oxysterols, cholesterol and 25-hydroxy-vitamin D3 in human plasma by LC-UV-MS. <i>PLoS ONE</i> , 2015 , 10, e0123771	3.7	22
246	Disease modifying therapies use associated with comorbid autoimmune diseases in multiple sclerosis patients. <i>Multiple Sclerosis and Related Disorders</i> , 2015 , 4, 228-33	4	5
245	Reserve-building activities in multiple sclerosis patients and healthy controls: a descriptive study. <i>BMC Neurology</i> , 2015 , 15, 135	3.1	6
244	Immunologic and MRI markers of the therapeutic effect of IFN- β 1a in relapsing-remitting MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2015 , 2, e176	9.1	11
243	Comparative efficacy of interferon β versus glatiramer acetate for relapsing-remitting multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2015 , 86, 1016-20	5.5	12
242	Humoral Responses to Diverse Autoimmune Disease-Associated Antigens in Multiple Sclerosis. <i>PLoS ONE</i> , 2015 , 10, e0129503	3.7	6
241	Summary of evidence-based guideline: complementary and alternative medicine in multiple sclerosis: report of the guideline development subcommittee of the American Academy of Neurology. <i>Neurology</i> , 2014 , 82, 1083-92	6.5	125
240	Retinal nerve fiber layer thickness and thalamus pathology in multiple sclerosis patients. <i>European Journal of Neurology</i> , 2014 , 21, 1137-e61	6	15

239	Characteristics influencing therapy switch behavior after suboptimal response to first-line treatment in patients with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2014 , 20, 830-6	5	8
238	Protective environmental factors for neuromyelitis optica. <i>Neurology</i> , 2014 , 83, 1923-9	6.5	18
237	No regional gray matter atrophy differences between pediatric- and adult-onset relapsing-remitting multiple sclerosis. <i>Journal of Neuroimaging</i> , 2014 , 24, 63-7	2.8	3
236	Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis. <i>Cochrane Database of Systematic Reviews</i> , 2014 , CD009333		16
235	Phase white matter signal abnormalities in patients with clinically isolated syndrome and other neurologic disorders. <i>American Journal of Neuroradiology</i> , 2014 , 35, 1916-23	4.4	9
234	Subcortical deep gray matter pathology in patients with multiple sclerosis is associated with white matter lesion burden and atrophy but not with cortical atrophy: a diffusion tensor MRI study. <i>American Journal of Neuroradiology</i> , 2014 , 35, 912-9	4.4	32
233	Serum lipoprotein composition and vitamin D metabolite levels in clinically isolated syndromes: Results from a multi-center study. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2014 , 143, 424-33	5.1	13
232	Apolipoproteins are associated with new MRI lesions and deep grey matter atrophy in clinically isolated syndromes. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014 , 85, 859-64	5.5	27
231	MRI segmentation analysis in temporal lobe and idiopathic generalized epilepsy. <i>BMC Neurology</i> , 2014 , 14, 131	3.1	7
230	Laquinimod therapy in multiple sclerosis: a comprehensive review. <i>Neurology and Therapy</i> , 2014 , 3, 29-39	4.6	9
229	Prevalence of radiologically isolated syndrome and white matter signal abnormalities in healthy relatives of patients with multiple sclerosis. <i>American Journal of Neuroradiology</i> , 2014 , 35, 106-12	4.4	37
228	Aqueductal cerebrospinal fluid pulsatility in healthy individuals is affected by impaired cerebral venous outflow. <i>Journal of Magnetic Resonance Imaging</i> , 2014 , 40, 1215-22	5.6	22
227	Osteoporosis and multiple sclerosis: risk factors, pathophysiology, and therapeutic interventions. <i>CNS Drugs</i> , 2014 , 28, 731-42	6.7	27
226	Diffusion tensor MRI alterations of subcortical deep gray matter in clinically isolated syndrome. <i>Journal of the Neurological Sciences</i> , 2014 , 338, 128-34	3.2	16
225	Cognitive deficits in pediatric-onset multiple sclerosis: what does the future hold?. <i>Neurodegenerative Disease Management</i> , 2014 , 4, 137-46	2.8	4
224	Longitudinal evaluation of cognitive functioning in pediatric multiple sclerosis: report from the US Pediatric Multiple Sclerosis Network. <i>Multiple Sclerosis Journal</i> , 2014 , 20, 1502-10	5	56
223	Negative work events and accommodations in employed multiple sclerosis patients. <i>Multiple Sclerosis Journal</i> , 2014 , 20, 116-9	5	31
222	MS disease activity in RESTORE: a randomized 24-week natalizumab treatment interruption study. <i>Neurology</i> , 2014 , 82, 1491-8	6.5	141

221	Transitions between SNF and home-based care in patients with multiple sclerosis. <i>NeuroRehabilitation</i> , 2014 , 34, 531-40	2	4
220	Prospective randomized trial of venous angioplasty in MS (PREMiSe). <i>Neurology</i> , 2014 , 83, 441-9	6.5	29
219	Natalizumab for multiple sclerosis: appraising risk versus benefit, a seemingly demanding tango. <i>Expert Opinion on Biological Therapy</i> , 2014 , 14, 115-26	5.4	11
218	Summary of evidence-based guideline: complementary and alternative medicine in multiple sclerosis: report of the Guideline Development Subcommittee of the American Academy of Neurology. <i>Neurology</i> , 2014 , 83, 1484-6	6.5	9
217	Characterizing cognitive function during relapse in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2014 , 20, 1745-52	5	69
216	Tract-based spatial statistics analysis of diffusion-tensor imaging data in pediatric- and adult-onset multiple sclerosis. <i>Human Brain Mapping</i> , 2014 , 35, 53-60	5.9	9
215	Humoral responses to herpesviruses are associated with neurodegeneration after a demyelinating event: results from the multi-center set study. <i>Journal of Neuroimmunology</i> , 2014 , 273, 58-64	3.5	16
214	Effect of treatment with interferon beta-1a on changes in voxel-wise magnetization transfer ratio in normal appearing brain tissue and lesions of patients with relapsing-remitting multiple sclerosis: a 24-week, controlled pilot study. <i>PLoS ONE</i> , 2014 , 9, e91098	3.7	13
213	Results from the 5-year, phase IV RENEW (Registry to Evaluate Novantrone Effects in Worsening Multiple Sclerosis) study. <i>BMC Neurology</i> , 2013 , 13, 80	3.1	23
212	Retinal nerve fiber thickness and MRI white matter abnormalities in healthy relatives of multiple sclerosis patients. <i>Clinical Neurology and Neurosurgery</i> , 2013 , 115 Suppl 1, S49-54	2	2
211	Cholesterol affects retinal nerve fiber layer thickness in patients with multiple sclerosis with optic neuritis. <i>European Journal of Neurology</i> , 2013 , 20, 1264-71	6	13
210	Multimodal noninvasive and invasive imaging of extracranial venous abnormalities indicative of CCSVI: results of the PREMiSe pilot study. <i>BMC Neurology</i> , 2013 , 13, 151	3.1	12
209	The neurological disease ontology. <i>Journal of Biomedical Semantics</i> , 2013 , 4, 42	2.2	24
208	Quantitative MRI analysis in children with multiple sclerosis: a multicenter feasibility pilot study. <i>BMC Neurology</i> , 2013 , 13, 173	3.1	2
207	Changes of cine cerebrospinal fluid dynamics in patients with multiple sclerosis treated with percutaneous transluminal angioplasty: a case-control study. <i>Journal of Vascular and Interventional Radiology</i> , 2013 , 24, 829-38	2.4	29
206	Direct and indirect cost burden associated with multiple sclerosis relapses: excess costs of persons with MS and their spouse caregivers. <i>Journal of the Neurological Sciences</i> , 2013 , 330, 71-7	3.2	40
205	Interactions of serum cholesterol with anti-herpesvirus responses affect disease progression in clinically isolated syndromes. <i>Journal of Neuroimmunology</i> , 2013 , 263, 121-7	3.5	10
204	Comparison of intravascular ultrasound with conventional venography for detection of extracranial venous abnormalities indicative of chronic cerebrospinal venous insufficiency. <i>Journal of Vascular and Interventional Radiology</i> , 2013 , 24, 1487-98.e1	2.4	23

203	Gray matter SWI-filtered phase and atrophy are linked to disability in MS. <i>Frontiers in Bioscience - Elite</i> , 2013 , 5, 525-32	1.6	18
202	Lisdexamfetamine dimesylate improves processing speed and memory in cognitively impaired MS patients: a phase II study. <i>Journal of Neurology</i> , 2013 , 260, 489-97	5.5	29
201	Interdependence and contributions of sun exposure and vitamin D to MRI measures in multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2013 , 84, 1075-81	5.5	28
200	Speech and pause characteristics in multiple sclerosis: a preliminary study of speakers with high and low neuropsychological test performance. <i>Clinical Linguistics and Phonetics</i> , 2013 , 27, 134-51	1.4	30
199	Iron content of the pulvinar nucleus of the thalamus is increased in adolescent multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2013 , 19, 567-76	5	22
198	Influence of personality on the relationship between gray matter volume and neuropsychiatric symptoms in multiple sclerosis. <i>Psychosomatic Medicine</i> , 2013 , 75, 253-61	3.7	20
197	Clinical significance of atrophy and white matter mean diffusivity within the thalamus of multiple sclerosis patients. <i>Multiple Sclerosis Journal</i> , 2013 , 19, 1478-84	5	71
196	MRI characteristics of familial and sporadic multiple sclerosis patients. <i>Multiple Sclerosis Journal</i> , 2013 , 19, 1145-52	5	6
195	Lipid profiles are associated with lesion formation over 24 months in interferon- β treated patients following the first demyelinating event. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2013 , 84, 1186-91	5.5	87
194	Antibody response to common viruses and human leukocyte antigen-DRB1 in pediatric multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2013 , 19, 891-5	5	27
193	Fatigue and depression in children with demyelinating disorders. <i>Journal of Child Neurology</i> , 2013 , 28, 713-8	2.5	49
192	Funding CCSVI research is/was a waste of valuable time, money and intellectual energy: no. <i>Multiple Sclerosis Journal</i> , 2013 , 19, 858-60	5	7
191	Is There Extra Cost of Institutional Care for MS Patients?. <i>Multiple Sclerosis International</i> , 2013 , 2013, 713627	1.1	8
190	Influence of cognitive function on speech and articulation rate in multiple sclerosis. <i>Journal of the International Neuropsychological Society</i> , 2013 , 19, 173-80	3.1	33
189	Cognitive impairment occurs in children and adolescents with multiple sclerosis: results from a United States network. <i>Journal of Child Neurology</i> , 2013 , 28, 102-7	2.5	103
188	Active cognitive reserve influences the regional atrophy to cognition link in multiple sclerosis. <i>Journal of the International Neuropsychological Society</i> , 2013 , 19, 1128-33	3.1	17
187	Environmental factors associated with disease progression after the first demyelinating event: results from the multi-center SET study. <i>PLoS ONE</i> , 2013 , 8, e53996	3.7	50
186	Impact of diagnosis and early treatment on the course of multiple sclerosis. <i>American Journal of Managed Care</i> , 2013 , 19, s321-31	2.1	60

185	An update on new and emerging therapies for relapsing-remitting multiple sclerosis. <i>American Journal of Managed Care</i> , 2013 , 19, s343-54	2.1	17
184	Venous angioplasty in patients with multiple sclerosis: results of a pilot study. <i>European Journal of Vascular and Endovascular Surgery</i> , 2012 , 43, 116-22	2.3	64
183	Regarding CCSVI and MS: a never-ending story or a new chapter?. <i>European Journal of Vascular and Endovascular Surgery</i> , 2012 , 43, 129-30	2.3	2
182	Regarding CCSVI: is blinding the key?. <i>European Journal of Vascular and Endovascular Surgery</i> , 2012 , 43, 126	2.3	
181	Associations of moderate alcohol consumption with clinical and MRI measures in multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2012 , 243, 61-8	3.5	20
180	Basal ganglia, thalamus and neocortical atrophy predicting slowed cognitive processing in multiple sclerosis. <i>Journal of Neurology</i> , 2012 , 259, 139-46	5.5	227
179	Voxel-wise magnetization transfer imaging study of effects of natalizumab and IFNβ1a in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2012 , 18, 1125-34	5	29
178	Role of venoplasty for treatment of multiple sclerosis: value of open-label studies and surrogate treatment outcomes. <i>Journal of Vascular and Interventional Radiology</i> , 2012 , 23, 1308-10	2.4	7
177	Clinical correlates of chronic cerebrospinal venous insufficiency in multiple sclerosis. <i>BMC Neurology</i> , 2012 , 12, 26	3.1	12
176	Abnormal subcortical deep-gray matter susceptibility-weighted imaging filtered phase measurements in patients with multiple sclerosis: a case-control study. <i>NeuroImage</i> , 2012 , 59, 331-9	7.9	160
175	The nervous systemB potential role in multiple sclerosis associated bone loss. <i>Journal of the Neurological Sciences</i> , 2012 , 319, 8-14	3.2	9
174	Limb ataxia originating from peri-central sulcus demyelinating lesion in multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2012 , 320, 136-40	3.2	6
173	The management of pediatric multiple sclerosis. <i>Journal of Child Neurology</i> , 2012 , 27, 1384-93	2.5	10
172	Iron deposition in multiple sclerosis lesions measured by susceptibility-weighted imaging filtered phase: a case control study. <i>Journal of Magnetic Resonance Imaging</i> , 2012 , 36, 73-83	5.6	55
171	Cine cerebrospinal fluid imaging in multiple sclerosis. <i>Journal of Magnetic Resonance Imaging</i> , 2012 , 36, 825-34	5.6	37
170	Patterns of dietary and herbal supplement use by multiple sclerosis patients. <i>Journal of Neurology</i> , 2012 , 259, 637-44	5.5	24
169	Additional efficacy endpoints from pivotal natalizumab trials in relapsing-remitting MS. <i>Journal of Neurology</i> , 2012 , 259, 898-905	5.5	54
168	Unemployment in multiple sclerosis: the contribution of personality and disease. <i>Multiple Sclerosis Journal</i> , 2012 , 18, 647-53	5	123

167	Comparison of standard 1.5 T vs. 3 T optimized protocols in patients treated with glatiramer acetate. A serial MRI pilot study. <i>International Journal of Molecular Sciences</i> , 2012 , 13, 5659-73	6.3	1
166	Multiple sclerosis in 2011: Advances in therapy, imaging and risk factors in MS. <i>Nature Reviews Neurology</i> , 2012 , 8, 66-8	15	8
165	Vitamin D and multiple sclerosis. <i>Neurologist</i> , 2012 , 18, 179-83	1.6	16
164	Cognitive impairment is associated with reduced bone mass in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2012 , 18, 1459-65	5	15
163	Randomized controlled trial of atorvastatin in clinically isolated syndrome: the STAyCIS study. <i>Neurology</i> , 2012 , 78, 1171-8	6.5	40
162	Intra- and extraluminal structural and functional venous anomalies in multiple sclerosis, as evidenced by 2 noninvasive imaging techniques. <i>American Journal of Neuroradiology</i> , 2012 , 33, 16-23	4.4	39
161	No association between conventional brain MR imaging and chronic cerebrospinal venous insufficiency in multiple sclerosis. <i>American Journal of Neuroradiology</i> , 2012 , 33, 1913-7	4.4	13
160	Regression-based norms improve the sensitivity of the National MS Society Consensus Neuropsychological Battery for Pediatric Multiple Sclerosis (NBPMS). <i>Clinical Neuropsychologist</i> , 2012 , 26, 985-1002	4.4	19
159	Iron deposition on SWI-filtered phase in the subcortical deep gray matter of patients with clinically isolated syndrome may precede structure-specific atrophy. <i>American Journal of Neuroradiology</i> , 2012 , 33, 1596-601	4.4	51
158	Heart disease, overweight, and cigarette smoking are associated with increased prevalence of extra-cranial venous abnormalities. <i>Neurological Research</i> , 2012 , 34, 819-27	2.7	9
157	Anti-phospholipid antibodies are associated with response to interferon-beta1a treatment in MS: results from a 3-year longitudinal study. <i>Neurological Research</i> , 2012 , 34, 761-9	2.7	10
156	Arterial, venous and other vascular risk factors in multiple sclerosis. <i>Neurological Research</i> , 2012 , 34, 754-60	2.7	18
155	Sensitivity and specificity of SWI venography for detection of cerebral venous alterations in multiple sclerosis. <i>Neurological Research</i> , 2012 , 34, 793-801	2.7	7
154	Comparison of a 1.5T standard vs. 3T optimized protocols in multiple sclerosis patients. <i>Minerva Medica</i> , 2012 , 103, 97-102	2.2	2
153	Upper and lower extremity motor function and cognitive impairment in multiple sclerosis. <i>Journal of the International Neuropsychological Society</i> , 2011 , 17, 643-53	3.1	97
152	The rs2030324 SNP of brain-derived neurotrophic factor (BDNF) is associated with visual cognitive processing in multiple sclerosis. <i>Pathophysiology</i> , 2011 , 18, 43-52	1.8	18
151	Effect of Met66 allele of the BDNF rs6265 SNP on regional gray matter volumes in patients with multiple sclerosis: A voxel-based morphometry study. <i>Pathophysiology</i> , 2011 , 18, 53-60	1.8	18
150	Glatiramer acetate recovers microscopic tissue damage in patients with multiple sclerosis. A case-control diffusion imaging study. <i>Pathophysiology</i> , 2011 , 18, 61-8	1.8	8

149	Inter-dependence of vitamin D levels with serum lipid profiles in multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2011 , 311, 86-91	3.2	25
148	Gerstmann-Strüssler-Scheinker syndrome masquerading as multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2011 , 309, 55-7	3.2	6
147	Regression-based pediatric norms for the brief visuospatial memory test: revised and the symbol digit modalities test. <i>Clinical Neuropsychologist</i> , 2011 , 25, 402-12	4.4	25
146	Risk factors for chronic cerebrospinal venous insufficiency (CCSVI) in a large cohort of volunteers. <i>PLoS ONE</i> , 2011 , 6, e28062	3.7	31
145	HLA DRB1*1501 is only modestly associated with lesion burden at the first demyelinating event. <i>Journal of Neuroimmunology</i> , 2011 , 236, 76-80	3.5	10
144	Phytosterols ameliorate clinical manifestations and inflammation in experimental autoimmune encephalomyelitis. <i>Inflammation Research</i> , 2011 , 60, 457-65	7.2	36
143	Fingolimod: an oral disease-modifying therapy for relapsing multiple sclerosis. <i>Advances in Therapy</i> , 2011 , 28, 270-8	4.1	19
142	Decreased brain venous vasculature visibility on susceptibility-weighted imaging venography in patients with multiple sclerosis is related to chronic cerebrospinal venous insufficiency. <i>BMC Neurology</i> , 2011 , 11, 128	3.1	42
141	Hypoperfusion of brain parenchyma is associated with the severity of chronic cerebrospinal venous insufficiency in patients with multiple sclerosis: a cross-sectional preliminary report. <i>BMC Medicine</i> , 2011 , 9, 22	11.4	61
140	Serum lipid profiles are associated with disability and MRI outcomes in multiple sclerosis. <i>Journal of Neuroinflammation</i> , 2011 , 8, 127	10.1	143
139	Comment on "no evidence of chronic cerebrospinal venous insufficiency at multiple sclerosis onset". <i>Annals of Neurology</i> , 2011 , 69, 1062-3; author reply 1063	9.4	3
138	Common viruses associated with lower pediatric multiple sclerosis risk. <i>Neurology</i> , 2011 , 76, 1989-95	6.5	104
137	Use of MR venography for characterization of the extracranial venous system in patients with multiple sclerosis and healthy control subjects. <i>Radiology</i> , 2011 , 258, 562-70	20.5	74
136	Value of MR venography for detection of internal jugular vein anomalies in multiple sclerosis: a pilot longitudinal study. <i>American Journal of Neuroradiology</i> , 2011 , 32, 938-46	4.4	60
135	Disease progression in pediatric multiple sclerosis: disparities between physical and neurocognitive outcomes. <i>Expert Review of Neurotherapeutics</i> , 2011 , 11, 433-40	4.3	7
134	Vitamin D metabolites are associated with clinical and MRI outcomes in multiple sclerosis patients. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2011 , 82, 189-95	5.5	69
133	Visual-cognitive processing deficits in pediatric multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2011 , 17, 449-56	5	24
132	Multicenter randomized clinical trial of donepezil for memory impairment in multiple sclerosis. <i>Neurology</i> , 2011 , 76, 1500-7	6.5	102

131	The NEO-FFI in Multiple Sclerosis: internal consistency, factorial validity, and correspondence between self and informant reports. <i>Assessment</i> , 2011 , 18, 39-49	3.7	26
130	Multiple sclerosis therapies in pediatric patients with refractory multiple sclerosis. <i>Archives of Neurology</i> , 2011 , 68, 437-44		86
129	Chronic cerebrospinal venous insufficiency in multiple sclerosis: diagnostic, pathogenetic, clinical and treatment perspectives. <i>Expert Review of Neurotherapeutics</i> , 2011 , 11, 1277-94	4.3	39
128	Fingolimod for the treatment of relapsing multiple sclerosis. <i>Expert Review of Neurotherapeutics</i> , 2011 , 11, 165-83	4.3	21
127	Plasma pentosidine: a potential biomarker in the management of multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2011 , 17, 157-63	5	14
126	Change in quality of life in patients with relapsing-remitting multiple sclerosis over 2 years in relation to other clinical parameters: results from a trial of intramuscular interferon {beta}-1a. <i>Multiple Sclerosis Journal</i> , 2011 , 17, 734-42	5	19
125	Cost-effectiveness of disease-modifying therapy for multiple sclerosis: a population-based study. <i>Neurology</i> , 2011 , 77, 355-63	6.5	72
124	Prevalence, sensitivity, and specificity of chronic cerebrospinal venous insufficiency in MS. <i>Neurology</i> , 2011 , 77, 138-44	6.5	166
123	Chronic cerebrospinal vascular insufficiency is not associated with HLA DRB1*1501 status in multiple sclerosis patients. <i>PLoS ONE</i> , 2011 , 6, e16802	3.7	14
122	Sensitivity and specificity for screening of chronic cerebrospinal venous insufficiency using a multimodal non-invasive imaging approach in patients with multiple sclerosis. <i>Functional Neurology</i> , 2011 , 26, 205-14	2.2	23
121	Cognition and physical disability in predicting health-related quality of life in multiple sclerosis. <i>International Journal of MS Care</i> , 2011 , 13, 57-63	2.3	20
120	Intramuscular interferon beta-1a therapy in patients with relapsing-remitting multiple sclerosis: a 15-year follow-up study. <i>Multiple Sclerosis Journal</i> , 2010 , 16, 588-96	5	66
119	The utility of regression-based norms in interpreting the minimal assessment of cognitive function in multiple sclerosis (MACFIMS). <i>Journal of the International Neuropsychological Society</i> , 2010 , 16, 6-16	3.1	133
118	A randomized, blinded, parallel-group, pilot trial of mycophenolate mofetil (CellCept) compared with interferon beta-1a (Avonex) in patients with relapsing-remitting multiple sclerosis. <i>Therapeutic Advances in Neurological Disorders</i> , 2010 , 3, 15-28	6.6	24
117	Increased tissue damage and lesion volumes in African Americans with multiple sclerosis. <i>Neurology</i> , 2010 , 74, 538-44	6.5	42
116	Disability progression in a clinical trial of relapsing-remitting multiple sclerosis: eight-year follow-up. <i>Archives of Neurology</i> , 2010 , 67, 1329-35		51
115	Natalizumab in pediatric multiple sclerosis patients. <i>Therapeutic Advances in Neurological Disorders</i> , 2010 , 3, 293-9	6.6	30
114	Predicting loss of employment over three years in multiple sclerosis: clinically meaningful cognitive decline. <i>Clinical Neuropsychologist</i> , 2010 , 24, 1131-45	4.4	160

113	Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2010 , 292, 28-35	3.2	50
112	Ultrasensitive quantification of serum vitamin D metabolites using selective solid-phase extraction coupled to microflow liquid chromatography and isotope-dilution mass spectrometry. <i>Analytical Chemistry</i> , 2010 , 82, 2488-97	7.8	86
111	Cerebellar mutism in pediatric acute disseminated encephalomyelitis. <i>Pediatric Neurology</i> , 2010 , 42, 259-66	2.6	27
110	Psychometrics and normative data for the Multiple Sclerosis Functional Composite: replacing the PASAT with the Symbol Digit Modalities Test. <i>Multiple Sclerosis Journal</i> , 2010 , 16, 228-37	5	189
109	Treatment of multiple sclerosis in children and adolescents. <i>Expert Opinion on Pharmacotherapy</i> , 2010 , 11, 505-20	4	21
108	MRI characteristics of patients with antiphospholipid syndrome and multiple sclerosis. <i>Journal of Neurology</i> , 2010 , 257, 63-71	5.5	20
107	Multiple sclerosis: predicting risk and delaying progression. <i>Lancet Neurology</i> , 2010 , 9, 7-9	24.1	3
106	Anti-myelin antibodies modulate clinical expression of childhood multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2010 , 223, 92-9	3.5	47
105	Phytosterols (PS) as immunomodulators of Multiple Sclerosis (MS). <i>FASEB Journal</i> , 2010 , 24, 332.8	0.9	
104	Use of neck magnetic resonance venography, Doppler sonography and selective venography for diagnosis of chronic cerebrospinal venous insufficiency: a pilot study in multiple sclerosis patients and healthy controls. <i>International Angiology</i> , 2010 , 29, 127-39	2.2	64
103	CSF dynamics and brain volume in multiple sclerosis are associated with extracranial venous flow anomalies: a pilot study. <i>International Angiology</i> , 2010 , 29, 140-8	2.2	21
102	Chronic cerebrospinal venous insufficiency and iron deposition on susceptibility-weighted imaging in patients with multiple sclerosis: a pilot case-control study. <i>International Angiology</i> , 2010 , 29, 158-75	2.2	52
101	Memory impairment in multiple sclerosis: correlation with deep grey matter and mesial temporal atrophy. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2009 , 80, 201-6	5.5	139
100	Retinal nerve fiber thickness in inflammatory demyelinating diseases of childhood onset. <i>Multiple Sclerosis Journal</i> , 2009 , 15, 802-10	5	45
99	Subjective fatigue is not associated with cognitive impairment in multiple sclerosis: cross-sectional and longitudinal analysis. <i>Multiple Sclerosis Journal</i> , 2009 , 15, 998-1005	5	72
98	Magnetic resonance imaging characteristics of children and adults with paediatric-onset multiple sclerosis. <i>Brain</i> , 2009 , 132, 3392-400	11.2	105
97	Smoking is associated with increased lesion volumes and brain atrophy in multiple sclerosis. <i>Neurology</i> , 2009 , 73, 504-10	6.5	100
96	Epstein-Barr virus is associated with grey matter atrophy in multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2009 , 80, 620-5	5.5	49

95	Gene-environment interactions between HLA B7/A2, EBV antibodies are associated with MRI injury in multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2009 , 209, 123-30	3.5	30
94	Mechanisms of interferon-beta effects on bone homeostasis. <i>Biochemical Pharmacology</i> , 2009 , 77, 1757-62		33
93	The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL. <i>Journal of Neurology</i> , 2009 , 256, 405-15	5.5	164
92	Gender-related differences in MS: a study of conventional and nonconventional MRI measures. <i>Multiple Sclerosis Journal</i> , 2009 , 15, 345-54	5	46
91	Comparison of the immunomodulatory effects of the plant sterol beta-sitosterol to simvastatin in peripheral blood cells from multiple sclerosis patients. <i>International Immunopharmacology</i> , 2009 , 9, 153-7	5.8	43
90	Personality traits in women with multiple sclerosis: discrepancy in patient/partner report and disease course. <i>Journal of Psychosomatic Research</i> , 2009 , 66, 147-54	4.1	15
89	Sensitivity of conventional memory tests in multiple sclerosis: comparing the Rao Brief Repeatable Neuropsychological Battery and the Minimal Assessment of Cognitive Function in MS. <i>Multiple Sclerosis Journal</i> , 2009 , 15, 1077-84	5	155
88	Recognizing and treating suboptimally controlled multiple sclerosis: steps toward regaining command. <i>Current Medical Research and Opinion</i> , 2009 , 25, 2459-70	2.5	21
87	The severity of chronic cerebrospinal venous insufficiency in patients with multiple sclerosis is related to altered cerebrospinal fluid dynamics. <i>Functional Neurology</i> , 2009 , 24, 133-8	2.2	67
86	Intense immunosuppression in patients with rapidly worsening multiple sclerosis: treatment guidelines for the clinician. <i>Lancet Neurology</i> , 2008 , 7, 173-83	24.1	62
85	Genomic effects of once-weekly, intramuscular interferon-beta1a treatment after the first dose and on chronic dosing: Relationships to 5-year clinical outcomes in multiple sclerosis patients. <i>Journal of Neuroimmunology</i> , 2008 , 205, 113-25	3.5	32
84	Quercetin and interferon-beta modulate immune response(s) in peripheral blood mononuclear cells isolated from multiple sclerosis patients. <i>Journal of Neuroimmunology</i> , 2008 , 205, 142-7	3.5	76
83	Retinal nerve fiber layer thickness is associated with brain MRI outcomes in multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2008 , 268, 12-7	3.2	129
82	Interferon-beta treatment for relapsing multiple sclerosis. <i>Expert Opinion on Biological Therapy</i> , 2008 , 8, 1435-47	5.4	33
81	Soluble receptor for advanced glycation end products in multiple sclerosis: a potential marker of disease severity. <i>Multiple Sclerosis Journal</i> , 2008 , 14, 759-63	5	38
80	Neuromyelitis optica immunoglobulins as a marker of disease activity and response to therapy in patients with neuromyelitis optica. <i>Multiple Sclerosis Journal</i> , 2008 , 14, 1061-7	5	33
79	Repeated assessment of neuropsychological deficits in multiple sclerosis using the Symbol Digit Modalities Test and the MS Neuropsychological Screening Questionnaire. <i>Multiple Sclerosis Journal</i> , 2008 , 14, 940-6	5	146
78	Comparison of three different methods for measurement of cervical cord atrophy in multiple sclerosis. <i>American Journal of Neuroradiology</i> , 2008 , 29, 319-25	4.4	57

77	Cortical atrophy and personality in multiple sclerosis. <i>Neuropsychology</i> , 2008 , 22, 432-41	3.8	39
76	Validity of the Wisconsin Card Sorting and Delis-Kaplan Executive Function System (DKEFS) Sorting Tests in multiple sclerosis. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2007 , 29, 215-23	2.1	66
75	Thalamic atrophy and cognition in multiple sclerosis. <i>Neurology</i> , 2007 , 69, 1213-23	6.5	363
74	Health-related quality of life in multiple sclerosis: effects of natalizumab. <i>Annals of Neurology</i> , 2007 , 62, 335-46	9.4	136
73	Pharmacogenetics of MXA SNPs in interferon-beta treated multiple sclerosis patients. <i>Journal of Neuroimmunology</i> , 2007 , 182, 236-9	3.5	34
72	Clinical and MRI correlates of autoreactive antibodies in multiple sclerosis patients. <i>Journal of Neuroimmunology</i> , 2007 , 187, 159-65	3.5	40
71	Immune cell BDNF secretion is associated with white matter volume in multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2007 , 188, 167-74	3.5	49
70	New MRI criteria in the diagnosis of multiple sclerosis. <i>Lancet Neurology, The</i> , 2007 , 6, 664-5	24.1	5
69	Clinical features and viral serologies in children with multiple sclerosis: a multinational observational study. <i>Lancet Neurology, The</i> , 2007 , 6, 773-81	24.1	249
68	MRI features of pediatric multiple sclerosis. <i>Neurology</i> , 2007 , 68, S46-53	6.5	57
67	Clinical features of children and adolescents with multiple sclerosis. <i>Neurology</i> , 2007 , 68, S37-45	6.5	91
66	Diffusion-weighted imaging predicts cognitive impairment in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2007 , 13, 722-30	5	81
65	The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL. <i>Neurology</i> , 2007 , 69, 1391-403	6.5	263
64	Preservation of gray matter volume in multiple sclerosis patients with the Met allele of the rs6265 (Val66Met) SNP of brain-derived neurotrophic factor. <i>Human Molecular Genetics</i> , 2007 , 16, 2659-68	5.6	79
63	An association between autoreactive antibodies and anti-interferon-beta antibodies in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2007 , 13, 895-9	5	11
62	Screening for cognitive impairment in multiple sclerosis using the Symbol digit Modalities Test. <i>Multiple Sclerosis Journal</i> , 2007 , 13, 52-7	5	238
61	Quantitative diffusion weighted imaging measures in patients with multiple sclerosis. <i>NeuroImage</i> , 2007 , 36, 746-54	7.9	42
60	Independent contributions of cortical gray matter atrophy and ventricle enlargement for predicting neuropsychological impairment in multiple sclerosis. <i>NeuroImage</i> , 2007 , 36, 1294-300	7.9	100

59	Dynamics of interferon-beta modulated mRNA biomarkers in multiple sclerosis patients with anti-interferon-beta neutralizing antibodies. <i>Journal of Neuroimmunology</i> , 2006 , 176, 125-33	3.5	40
58	Cognitive impairment is associated with subcortical magnetic resonance imaging grey matter T2 hypointensity in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2006 , 12, 437-44	5	131
57	Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. <i>New England Journal of Medicine</i> , 2006 , 354, 911-23	59.2	1048
56	Study of mitoxantrone for the treatment of recurrent neuromyelitis optica (Devic disease). <i>Archives of Neurology</i> , 2006 , 63, 957-63		144
55	Neocortical atrophy, third ventricular width, and cognitive dysfunction in multiple sclerosis. <i>Archives of Neurology</i> , 2006 , 63, 1301-6		253
54	Interferon-beta modulates bone-associated cytokines and osteoclast precursor activity in multiple sclerosis patients. <i>Multiple Sclerosis Journal</i> , 2006 , 12, 541-50	5	30
53	Gray and white matter brain atrophy and neuropsychological impairment in multiple sclerosis. <i>Neurology</i> , 2006 , 66, 685-92	6.5	233
52	Interferon inhibitory activity in patients with multiple sclerosis. <i>Archives of Neurology</i> , 2006 , 63, 1579-84		15
51	Validity of the minimal assessment of cognitive function in multiple sclerosis (MACFIMS). <i>Journal of the International Neuropsychological Society</i> , 2006 , 12, 549-58	3.1	494
50	Prediction of longitudinal brain atrophy in multiple sclerosis by gray matter magnetic resonance imaging T2 hypointensity. <i>Archives of Neurology</i> , 2005 , 62, 1371-6		83
49	The relationship between whole brain volume and disability in multiple sclerosis: a comparison of normalized gray vs. white matter with misclassification correction. <i>NeuroImage</i> , 2005 , 26, 1068-77	7.9	142
48	Low fat dietary intervention with omega-3 fatty acid supplementation in multiple sclerosis patients. <i>Prostaglandins Leukotrienes and Essential Fatty Acids</i> , 2005 , 73, 397-404	2.8	137
47	Predicting quality of life in multiple sclerosis: accounting for physical disability, fatigue, cognition, mood disorder, personality, and behavior change. <i>Journal of the Neurological Sciences</i> , 2005 , 231, 29-34	3.2	378
46	MRI T2 hypointensity of the dentate nucleus is related to ambulatory impairment in multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2005 , 234, 17-24	3.2	92
45	Interpreting patient/informant discrepancies of reported cognitive symptoms in MS. <i>Journal of the International Neuropsychological Society</i> , 2005 , 11, 574-83	3.1	78
44	Estimating long-term effects of disease-modifying drug therapy in multiple sclerosis patients. <i>Multiple Sclerosis Journal</i> , 2005 , 11, 626-34	5	48
43	A randomized blinded trial of combination therapy with cyclophosphamide in patients-with active multiple sclerosis on interferon beta. <i>Multiple Sclerosis Journal</i> , 2005 , 11, 573-82	5	67
42	Regional lobar atrophy predicts memory impairment in multiple sclerosis. <i>American Journal of Neuroradiology</i> , 2005 , 26, 1824-31	4.4	69

41	Prediction of neuropsychological impairment in multiple sclerosis: comparison of conventional magnetic resonance imaging measures of atrophy and lesion burden. <i>Archives of Neurology</i> , 2004 , 61, 226-30		304
40	Reliable screening for neuropsychological impairment in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2004 , 10, 675-8	5	194
39	Clinical characteristics of African Americans vs Caucasian Americans with multiple sclerosis. <i>Neurology</i> , 2004 , 63, 2039-45	6.5	214
38	Multiple sclerosis gender issues: clinical practices of women neurologists. <i>Multiple Sclerosis Journal</i> , 2004 , 10, 582-8	5	46
37	Combination therapy for multiple sclerosis: the treatment strategy of the future?. <i>CNS Drugs</i> , 2004 , 18, 777-92	6.7	18
36	Functional imaging during covert auditory attention in multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2004 , 218, 9-15	3.2	14
35	Risk of bone loss in men with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2004 , 10, 170-5	5	87
34	Construct validity and frequency of euphoria sclerotica in multiple sclerosis. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2004 , 16, 350-6	2.7	32
33	Whole-brain atrophy in multiple sclerosis measured by automated versus semiautomated MR imaging segmentation. <i>American Journal of Neuroradiology</i> , 2004 , 25, 985-96	4.4	39
32	Validity of the Beck Depression Inventory-Fast Screen in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2003 , 9, 393-6	5	244
31	Genomic effects of IFN-beta in multiple sclerosis patients. <i>Journal of Immunology</i> , 2003 , 171, 2694-702	5.3	103
30	Multiple sclerosis characteristics in African American patients in the New York State Multiple Sclerosis Consortium. <i>Multiple Sclerosis Journal</i> , 2003 , 9, 293-8	5	92
29	Dynamics of immune cell trafficking in interferon-beta treated multiple sclerosis patients. <i>Journal of Neuroimmunology</i> , 2003 , 139, 84-92	3.5	20
28	Thalamic Involvement in Multiple Sclerosis: A Diffusion-Weighted Magnetic Resonance Imaging Study. <i>Journal of Neuroimaging</i> , 2003 , 13, 307-314	2.8	76
27	Sex differences in in vitro pro-inflammatory cytokine production from peripheral blood of multiple sclerosis patients. <i>Journal of the Neurological Sciences</i> , 2003 , 209, 93-9	3.2	62
26	Factors that predict health-related quality of life in patients with relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2003 , 9, 1-5	5	48
25	Pattern reversal visual evoked potentials as a measure of visual pathway pathology in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2003 , 9, 529-34	5	60
24	Thalamic Involvement in Multiple Sclerosis: A Diffusion-Weighted Magnetic Resonance Imaging Study 2003 , 13, 307		32

23	Thalamic involvement in multiple sclerosis: a diffusion-weighted magnetic resonance imaging study 2003 , 13, 307-14		21
22	In vivo gene expression revealed by cDNA arrays: the pattern in relapsing-remitting multiple sclerosis patients compared with normal subjects. <i>Journal of Neuroimmunology</i> , 2001 , 116, 213-9	3.5	89
21	Use of the Multiple Sclerosis Functional Composite to predict disability in relapsing MS. <i>Neurology</i> , 2001 , 56, 1324-30	6.5	109
20	What is new in the treatment of multiple sclerosis?. <i>Drugs</i> , 2000 , 59, 401-10	12.1	43
19	A meta-analysis of methylprednisolone in recovery from multiple sclerosis exacerbations. <i>Multiple Sclerosis Journal</i> , 2000 , 6, 267-273	5	4
18	Relationship between brain atrophy and disability: an 8-year follow-up study of multiple sclerosis patients. <i>Multiple Sclerosis Journal</i> , 2000 , 6, 373-377	5	17
17	Detection of cytochrome P450 and other drug-metabolizing enzyme mRNAs in peripheral blood mononuclear cells using DNA arrays. <i>Drug Metabolism and Disposition</i> , 2000 , 28, 987-93	4	19
16	Cerebrospinal fluid abnormalities in a phase III trial of Avonex (IFNbeta-1a) for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group. <i>Journal of Neuroimmunology</i> , 1999 , 93, 8-14	3.5	81
15	Results of an Ongoing, Open-Label, Safety-Extension Study of Interferon Beta-1a (Avonex) Treatment in Multiple Sclerosis. <i>International Journal of MS Care</i> , 1999 , 1, 3-11	2.3	2
14	Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group. <i>Annals of Neurology</i> , 1998 , 43, 79-87	9.4	310
13	HLA-DP: a class II restriction molecule involved in epitope spreading during the development of multiple sclerosis. <i>Human Immunology</i> , 1998 , 59, 15-24	2.3	39
12	Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Multiple Sclerosis Collaborative Research Group (MSCRG). <i>Neurology</i> , 1998 , 50, 1266-72	6.5	256
11	Devic's disease: Diagnostic and therapeutic challenge. <i>Multiple Sclerosis Journal</i> , 1997 , 3, 408-408	5	
10	TREATMENT OF FULMINANT MULTIPLE SCLEROSIS WITH INTRAVENOUS CYCLOPHOSPHAMIDE. <i>Neurologist</i> , 1997 , 3, 178-185	1.6	36
9	Prescribing recommendations for interferon-Beta in multiple sclerosis. <i>CNS Drugs</i> , 1997 , 8, 102-12	6.7	12
8	Management of multiple sclerosis. <i>New England Journal of Medicine</i> , 1997 , 337, 1604-11	59.2	152
7	Diversity and plasticity of self recognition during the development of multiple sclerosis. <i>Journal of Clinical Investigation</i> , 1997 , 99, 1682-90	15.9	133
6	Newer versus older treatments for relapsing-remitting multiple sclerosis. <i>Drug Safety</i> , 1996 , 14, 121-30	5.1	5

5	Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). <i>Annals of Neurology</i> , 1996 , 39, 285-94	9.4	2075
4	A phase III trial of intramuscular recombinant interferon beta as treatment for exacerbating-relapsing multiple sclerosis: design and conduct of study and baseline characteristics of patients. Multiple Sclerosis Collaborative Research Group (MSCRG). <i>Multiple Sclerosis Journal</i> , 1995 , 1, 118-35	5	85
3	Unusual long-standing Gd-DTPA enhancement in a chronic progressive myelopathy. <i>Journal of Computer Assisted Tomography</i> , 1995 , 19, 649-51	2.2	1
2	The interferons: biological effects, mechanisms of action, and use in multiple sclerosis. <i>Annals of Neurology</i> , 1995 , 37, 7-15	9.4	178
1	Management of pediatric multiple sclerosis632-644		